KR
KROS.US Keros Therapeutics Inc
- Market cap
- USD 202M
- P/E
- -
- P/B
- 0.73x
- ROE
- -18.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KROS.US undervalued?
Graham numberThe Graham number of Keros Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Keros Therapeutics Inc fundamental analysis
No fundamental analysis for Keros Therapeutics Inc yet.
Keros Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and …
Full company profileKeros Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Keros Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.0M | 10.0M | 2.50M | 20.1M | 20.0M | 151K | 3.55M | 244M | 78.1M |
| Gross Profit | -111K | -7.35M | -605K | 20.1M | -1.62M | 151K | 3.55M | 243M | - |
| Operating Income | -1.69M | -10.6M | -46.7M | -56.4M | -115M | -170M | -211M | 70.6M | -58.7M |
| EBITDA | -1.17M | -11.9M | -45.2M | -56.4M | -104M | -152M | -186M | 93.4M | -48.9M |
| Net Income | -1.34M | -12.3M | -45.4M | -58.7M | -105M | -153M | -187M | 87.0M | -51.0M |
| EPS | -0.15 | -1.39 | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 | 2.30 | -2.51 |
| Balance Sheet | |||||||||
| Total Assets | 27.4M | 11.0M | 269M | 255M | 307M | 370M | 616M | 338M | 307M |
| Total Liabilities | 14.7M | 5.50M | 7.72M | 12.1M | 29.4M | 37.8M | 44.3M | 34.9M | 28.3M |
| Shareholders' Equity | 12.8M | 5.45M | 262M | 243M | 277M | 332M | 572M | 303M | 279M |
| Cash & Short-term Investments | 23.3M | 7.02M | 266M | 230M | 279M | 331M | 560M | 287M | 259M |
| Total Debt | 2.56M | 5.33M | 899K | 1.09M | 13.3M | 14.4M | 18.9M | 16.9M | 15.1M |
| Cash Flow | |||||||||
| Operating Cash Flow | 7.04M | -16.0M | -36.9M | -62.1M | -70.1M | -125M | -161M | 108M | -27.4M |
| Capital Expenditure | 217K | 271K | 294K | 1.02M | 1.24M | 2.46M | 1.93M | 1.55M | 383K |
| Free Cash Flow | 6.83M | -16.3M | -37.2M | -63.2M | -71.3M | -127M | -163M | 106M | -27.8M |
| Ratios | |||||||||
| ROE | -10.5% | -226.5% | -17.3% | -24.2% | -37.7% | -46.1% | -32.8% | 28.7% | -18.3% |
| ROA | -4.9% | -112.7% | -16.8% | -23.0% | -34.1% | -41.3% | -30.4% | 25.7% | -16.6% |
| Net Profit Margin | -13.4% | -123.4% | -1,814.4% | -292.3% | -523.4% | -101,319.2% | -5,277.5% | 35.7% | -65.4% |
| Debt to Equity | 0.20x | 0.98x | 0.00x | 0.00x | 0.05x | 0.04x | 0.03x | 0.06x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Keros Therapeutics Inc dividends
Keros Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Keros Therapeutics Inc
- Insiders 4.62%
- Institutions 95.38%
- Public & others 0.00%
- Shares outstanding 19.6M
- Free float 17.6M
Top funds holding KROS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 595K | 3.03% | 0.00% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 465K | 2.37% | +1.26% | Sep 2026 |
| iShares Russell 2000 ETF | 464K | 2.37% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 382K | 1.95% | 0.00% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 292K | 1.49% | 0.00% | Aug 2026 |
| Bridge Builder Small Cap Fund | 270K | 1.38% | +66.38% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 259K | 1.32% | 0.00% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 193K | 0.98% | +1.63% | Sep 2026 |
| Fidelity Small Cap Index | 179K | 0.91% | -10.86% | Aug 2026 |
| iShares Russell 2000 Value ETF | 174K | 0.89% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 171K | 0.87% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap Value I | 163K | 0.83% | +54.13% | Sep 2026 |
| iShares Biotechnology ETF | 142K | 0.72% | -0.19% | Oct 2026 |
| Federated Hermes MDT Small Cap Growth IS | 116K | 0.59% | 0.00% | Sep 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 108K | 0.55% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 108K | 0.55% | +1.81% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 107K | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 105K | 0.53% | +0.21% | Oct 2026 |
| Fidelity Extended Market Index | 94.2K | 0.48% | +59.12% | Sep 2026 |
| BlackRock Advantage Small Cap Gr Instl | 76.7K | 0.39% | -8.02% | Sep 2026 |
Top institutions holding KROS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2.82M | 14.37% | +107.35% | Jun 2026 |
| BlackRock Inc | 2.79M | 14.24% | +15.86% | Jun 2026 |
| AQR Capital Management LLC | 968K | 4.93% | +138.06% | Jun 2026 |
| Vanguard Capital Management, LLC | 834K | 4.25% | +0.26% | Jun 2026 |
| Orbimed Advisors LLC | 759K | 3.87% | 0.00% | Jun 2026 |
| Federated Hermes Inc | 700K | 3.57% | +1.62% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 653K | 3.33% | -4.31% | Jun 2026 |
| Mackenzie Investments | 628K | 3.20% | +312.23% | Jun 2026 |
| Madison Avenue Partners, LP | 627K | 3.19% | 0.00% | Jun 2026 |
| Qube Research & Technologies | 609K | 3.10% | -16.01% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 605K | 3.09% | -14.25% | Jun 2026 |
| State Street Corp | 541K | 2.76% | -3.66% | Jun 2026 |
| Geode Capital Management, LLC | 511K | 2.60% | -25.04% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 404K | 2.06% | -12.36% | Sep 2026 |
| Citadel Advisors Llc | 396K | 2.02% | -2.60% | Jun 2026 |
| Renaissance Technologies Corp | 346K | 1.76% | -3.61% | Sep 2026 |
| D. E. Shaw & Co LP | 267K | 1.36% | -47.52% | Jun 2026 |
| Bridgeway Capital Management, LLC | 265K | 1.35% | +35.89% | Jun 2026 |
| Nuveen, LLC | 248K | 1.26% | -5.46% | Jun 2026 |
| ADAR1 Capital Management LLC | 247K | 1.26% | +153.62% | Jun 2026 |
Keros Therapeutics Inc company profile
- Company name
- Keros Therapeutics Inc
- Ticker
- KROS.US
- Exchange
- USA Stocks
- Listed since
- Apr 8, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 1050 Waltham Street, Lexington, MA, United States, 02421
- Phone
- 617 314 6297
- Website
- kerostx.com
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics Inc management
5- Dr. Jasbir S. Seehra Ph.D.President, CEO & Director · born 1956
- Ms. Esther Cho J.D.Chief Legal Officer & Secretary · born 1989
- Ms. Annita TaniniVP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer · born 1971
- Justin FrantzHead of Investor Relations
- Dr. Lorena Lerner Ph.D.Chief Scientific Officer · born 1972